<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK469816" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK469816/" /><meta name="ncbi_pagename" content="Rhabdoid Tumor Predisposition Syndrome - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Rhabdoid Tumor Predisposition Syndrome - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Rhabdoid Tumor Predisposition Syndrome" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/12/07" /><meta name="citation_author" content="Karolina Nemes" /><meta name="citation_author" content="Susanne Bens" /><meta name="citation_author" content="Franck Bourdeaut" /><meta name="citation_author" content="Martin Hasselblatt" /><meta name="citation_author" content="Marcel Kool" /><meta name="citation_author" content="Pascal Johann" /><meta name="citation_author" content="Uwe Kordes" /><meta name="citation_author" content="Reinhard Schneppenheim" /><meta name="citation_author" content="Reiner Siebert" /><meta name="citation_author" content="Michael C Frühwald" /><meta name="citation_pmid" content="29215836" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK469816/" /><meta name="citation_keywords" content="Rhabdoid Predisposition Syndrome" /><meta name="citation_keywords" content="RTPS" /><meta name="citation_keywords" content="Rhabdoid Predisposition Syndrome" /><meta name="citation_keywords" content="RTPS" /><meta name="citation_keywords" content="SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1" /><meta name="citation_keywords" content="Transcription activator BRG1" /><meta name="citation_keywords" content="SMARCA4" /><meta name="citation_keywords" content="SMARCB1" /><meta name="citation_keywords" content="Rhabdoid Tumor Predisposition Syndrome" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Rhabdoid Tumor Predisposition Syndrome" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Karolina Nemes" /><meta name="DC.Contributor" content="Susanne Bens" /><meta name="DC.Contributor" content="Franck Bourdeaut" /><meta name="DC.Contributor" content="Martin Hasselblatt" /><meta name="DC.Contributor" content="Marcel Kool" /><meta name="DC.Contributor" content="Pascal Johann" /><meta name="DC.Contributor" content="Uwe Kordes" /><meta name="DC.Contributor" content="Reinhard Schneppenheim" /><meta name="DC.Contributor" content="Reiner Siebert" /><meta name="DC.Contributor" content="Michael C Frühwald" /><meta name="DC.Date" content="2017/12/07" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK469816/" /><meta name="description" content="Rhabdoid tumor predisposition syndrome (RTPS) is characterized by a markedly increased risk of developing rhabdoid tumors – rare and highly aggressive malignant tumors occurring predominantly in infants and children younger than age three years. Rhabdoid tumors can occur in almost any anatomic location, commonly in the central nervous system (i.e., atypical teratoid/rhabdoid tumor [AT/RT]); more than 50% occur in the cerebellum." /><meta name="og:title" content="Rhabdoid Tumor Predisposition Syndrome" /><meta name="og:type" content="book" /><meta name="og:description" content="Rhabdoid tumor predisposition syndrome (RTPS) is characterized by a markedly increased risk of developing rhabdoid tumors – rare and highly aggressive malignant tumors occurring predominantly in infants and children younger than age three years. Rhabdoid tumors can occur in almost any anatomic location, commonly in the central nervous system (i.e., atypical teratoid/rhabdoid tumor [AT/RT]); more than 50% occur in the cerebellum." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK469816/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/rtps/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK469816/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8C0279E0406001000000000498017F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK469816_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK469816_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/retinoblastoma/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rcdp/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK469816_"><span class="title" itemprop="name">Rhabdoid Tumor Predisposition Syndrome</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Rhabdoid Predisposition Syndrome, RTPS</div><p class="contrib-group"><span itemprop="author">Karolina Nemes</span>, MD, PhD, <span itemprop="author">Susanne Bens</span>, MD, PhD, <span itemprop="author">Franck Bourdeaut</span>, MD, PhD, <span itemprop="author">Martin Hasselblatt</span>, MD, Prof, <span itemprop="author">Marcel Kool</span>, PhD, <span itemprop="author">Pascal Johann</span>, MD, <span itemprop="author">Uwe Kordes</span>, MD, <span itemprop="author">Reinhard Schneppenheim</span>, MD, PhD, Prof, <span itemprop="author">Reiner Siebert</span>, MD, Prof, and <span itemprop="author">Michael C Fr&#x000fc;hwald</span>, MD, PhD, Prof.</p><a data-jig="ncbitoggler" href="#__NBK469816_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK469816_ai__"><div class="contrib half_rhythm"><span itemprop="author">Karolina Nemes</span>, MD, PhD<div class="affiliation small">Swabian Children&#x02019;s Cancer Center<br />Children&#x02019;s Hospital Augsburg<br />Augsburg, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.grubsgua-mukinilk@semen.anilorak" class="oemail">ed.grubsgua-mukinilk@semen.anilorak</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Susanne Bens</span>, MD, PhD<div class="affiliation small">Institute of Human Genetics<br />University of Ulm &#x00026; University Hospital Ulm<br />Ulm, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.mlu-inu@sneb.ennasus" class="oemail">ed.mlu-inu@sneb.ennasus</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Franck Bourdeaut</span>, MD, PhD<div class="affiliation small">Pediatric Care and Research Center<br />Institute Curie<br />Paris Sciences et Lettres Research University<br />Paris, France<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.eiruc@tuaedruob.kcnarf" class="oemail">rf.eiruc@tuaedruob.kcnarf</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Martin Hasselblatt</span>, MD, Prof<div class="affiliation small">Institute of Neuropathology<br />University Hospital M&#x000fc;nster<br />M&#x000fc;nster, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.retsneumku@ttalblessah.nitram" class="oemail">ed.retsneumku@ttalblessah.nitram</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Marcel Kool</span>, PhD<div class="affiliation small">Division of Pediatric Neurooncology<br />German Cancer Research Center (DKFZ)<br />German Cancer Consortium (DKTK)<br />Heidelberg, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.grebledieh-zfkd@look.m" class="oemail">ed.grebledieh-zfkd@look.m</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Pascal Johann</span>, MD<div class="affiliation small">Division of Pediatric Neurooncology<br />German Cancer Research Center (DKFZ)<br />German Cancer Consortium (DKTK)<br />Heidelberg, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.grebledieh-inu.dem@nnahoj.lacsap" class="oemail">ed.grebledieh-inu.dem@nnahoj.lacsap</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Uwe Kordes</span>, MD<div class="affiliation small">Department of Pediatric Haematology and Oncology<br />University Medical Center Hamburg&#x02013;Eppendorf<br />Hamburg, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.eku@sedrok" class="oemail">ed.eku@sedrok</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Reinhard Schneppenheim</span>, MD, PhD, Prof<div class="affiliation small">Department of Pediatric Haematology and Oncology<br />University Medical Center Hamburg&#x02013;Eppendorf<br />Hamburg, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.eku@miehneppenhcs" class="oemail">ed.eku@miehneppenhcs</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Reiner Siebert</span>, MD, Prof<div class="affiliation small">Institute of Human Genetics<br />University of Ulm &#x00026; University Hospital Ulm<br />Ulm, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.mlu-inu@trebeis.renier" class="oemail">ed.mlu-inu@trebeis.renier</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Michael C Fr&#x000fc;hwald</span>, MD, PhD, Prof<div class="affiliation small">Swabian Children&#x02019;s Cancer Center<br />Children&#x02019;s Hospital Augsburg<br />Augsburg, Germany<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ed.grubsgua-mukinilk@dlawheurf.leahcim" class="oemail">ed.grubsgua-mukinilk@dlawheurf.leahcim</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">December 7, 2017</span>.</p><p><em>Estimated reading time: 25 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="rtps.Summary" itemprop="description"><h2 id="_rtps_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Rhabdoid tumor predisposition syndrome (RTPS) is characterized by a markedly increased risk of developing rhabdoid tumors &#x02013; rare and highly aggressive malignant tumors occurring predominantly in infants and children younger than age three years. Rhabdoid tumors can occur in almost any anatomic location, commonly in the central nervous system (i.e., atypical teratoid/rhabdoid tumor [AT/RT]); more than 50% occur in the cerebellum.</p><p>Other common locations include extracranial extrarenal malignant rhabdoid tumors (e.g., rhabdoid tumors of the head and neck, paravertebral muscles, liver, bladder, mediastinum, retroperitoneum, pelvis, and heart) (eMRT), rhabdoid tumor of the kidney (RTK), and possibly small-cell carcinoma of the ovary (hypercalcemic type). Individuals with RTPS typically present before age 12 months with synchronous tumors that exhibit aggressive clinical behavior.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of RTPS is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with a rhabdoid tumor and/or a family history of rhabdoid tumor and/or multiple SMARCA4- or SMARCB1-deficient tumors (synchronous or metachronous) and identification of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SMARCA4</i> or <i>SMARCB1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Due to the rarity of RTPS, standards for management are evolving. Most individuals are treated by intensive multimodal therapeutic strategies, according to institutional preference combining surgery, radiotherapy, and chemotherapy.</p><p><i>Prevention of primary manifestations:</i> Prophylactic bilateral oophorectomy may be discussed after childbearing.</p><p><i>Prevention of secondary manifestations:</i> Consider risk-reducing treatment strategies (e.g., postpone or replace radiotherapy with high-dose chemotherapy or proton beam therapy; targeted therapy used concomitantly with, or before, standard chemotherapy).</p><p><i>Surveillance:</i> From birth to age one year:</p><ul><li class="half_rhythm"><div>Monthly physical and neurologic examination, head ultrasound, and abdominal and pelvic ultrasound recommended.</div></li><li class="half_rhythm"><div>If not feasible for patients with AT/RT, monthly head ultrasound plus abdominal and pelvic ultrasound every two to three months is a minimum requirement. If fontanelle closes prematurely consider head MRI every two to three months.</div></li><li class="half_rhythm"><div>For patients with eMRT, RTK: monthly head, abdominal, and pelvic ultrasound examination.</div></li><li class="half_rhythm"><div>If ultrasound is not sufficient consider MRI at least every two to three months for affected site and ultrasound for all other sites. Whole-body MRI is desirable but not universally available.</div></li></ul><p>From age one year to age four to five years:</p><ul><li class="half_rhythm"><div>For patients with AT/RT: brain and total spine MRI every three months</div></li><li class="half_rhythm"><div>If available, consider whole-body MRI. (Note: Whole-body MRI resolution may not be sufficent for brain MRI, which would then need to be performed separately).</div></li><li class="half_rhythm"><div>For patients with eMRT, RTK: abdominal and pelvic ultrasound or MRI (or whole-body MRI) every three months.</div></li></ul><p>After age four years:</p><ul><li class="half_rhythm"><div>Twice-yearly physical examination in a tumor predisposition clinic with targeted imaging for symptomatic areas.</div></li><li class="half_rhythm"><div>For patients with <i>SMARCA4</i>-related SCCOHT: abdominal and pelvic ultrasound every six months.</div></li></ul><p><i>Evaluation of relatives at risk:</i> It is appropriate to evaluate apparently asymptomatic older and younger at-risk relatives of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in order to identify as early as possible those who would benefit from prompt initiation of screening, treatment, and preventive measures.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>RTPS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. The vast majority of individuals diagnosed with RTPS have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Most reported individuals diagnosed with <i>SMARCA4</i>-related RTPS inherited a pathogenic variant from an unaffected parent. Each child of an individual with a germline <i>SMARCA4</i> or <i>SMARCB1</i> pathogenic variant has a 50% chance of inheriting the pathogenic variant. However, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> appears to be incomplete and the types of RTPS-related tumors can vary among different members of the same family. Prenatal diagnosis for pregnancies at increased risk is possible if the pathogenic variant in the family is known.</p></div></div><div id="rtps.Diagnosis"><h2 id="_rtps_Diagnosis_">Diagnosis</h2><div id="rtps.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Rhabdoid tumor predisposition syndrome (RTPS) <b>should be suspected</b> in an individual with any of the following clinical or laboratory features.</p><p><b>Clinical features.</b> Any rhabdoid tumor with the following features is particularly suspicious:</p><ul><li class="half_rhythm"><div>Congenital presentation (i.e., <a class="def" href="/books/n/gene/glossary/def-item/prenatal-diagnosis/">prenatal diagnosis</a> or symptoms within the first 28 days of life)</div></li><li class="half_rhythm"><div>Early-onset rhabdoid tumor (age &#x0003c;12 months)</div></li><li class="half_rhythm"><div>Advanced stage of rhabdoid tumor (RT) at diagnosis (e.g., &#x0003e;<i>M<sub>1</sub></i> by Chang classification; Stage &#x02265;II in extracranial RT [<a class="bk_pop" href="#rtps.REF.harisiadis.1977.833">Harisiadis &#x00026; Chang 1977</a>])</div></li><li class="half_rhythm"><div>Synchronous rhabdoid tumors (&#x0003e;1 primary rhabdoid tumor)</div></li><li class="half_rhythm"><div>Family history of rhabdoid tumor, small-cell carcinoma of the ovary hypercalcemic type, or other malignant entities such as cribriform neuroepithelial tumor, malignant peripheral nerve sheath tumor, and non-malignant schwannoma or meningioma</div></li><li class="half_rhythm"><div>Family history of RTPS</div></li></ul><p>Given the limited patient data available, <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for RTPS is recommended in any individual with:</p><ul><li class="half_rhythm"><div>A rhabdoid tumor (at any age), <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> rhabdoid tumors, multifocal tumors, or <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a>-onset tumors;</div></li><li class="half_rhythm"><div>A SMARCB1-deficient tumor (as defined by histology, rhabdoid and non-rhabdoid) with a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> history of rhabdoid tumor OR non-specified cancer in early childhood (age &#x0003c;5 years);</div></li><li class="half_rhythm"><div>A SMARCA4-deficient tumor (as defined by histology, rhabdoid and non-rhabdoid) with a <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> history of rhabdoid tumor OR non-specified cancer in early childhood (age &#x0003c;5 years).</div></li></ul><p>Note: (1) It remains to be determined whether adult-onset rhabdoid tumors are caused by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>SMARCA4</i> or <i>SMARCB1</i>. (2) As morphologic rhabdoid features may not be present in all rhabdoid tumor biopsies because of inter- and intratumoral heterogeneity, any small blue round cell tumors in infants and young children should be evaluated for absence of nuclear SMARCA4 or SMARCB1 staining.</p><p><b>Laboratory features on tumor tissue</b></p><ul><li class="half_rhythm"><div><b>Immunohistochemistry.</b> Absence of SMARCA4 (formerly BRG-1) or SMARCB1 (formerly INI-1) staining in tumor tissue</div></li><li class="half_rhythm"><div><b>Molecular genetic testing.</b> Somatic <i>SMARCA4</i> or <i>SMARCB1</i> pathogenic variants identified in a rhabdoid tumor. Note: Fresh-frozen tumor is preferable; formalin-fixed, paraffin-embedded samples may also be suitable.</div></li></ul></div><div id="rtps.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>There is currently no consensus regarding formal diagnostic criteria for rhabdoid tumor predisposition syndrome (RTPS).</p><p>The diagnosis of RTPS <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with both of the following:</p><ul><li class="half_rhythm"><div>A rhabdoid tumor and/or a family history of rhabdoid tumor and/or multiple SMARCA4- or SMARCB1-deficient tumors (synchronous or metachronous)</div></li><li class="half_rhythm"><div>Identification of a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SMARCA4</i> or <i>SMARCB1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK469816/table/rtps.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="figrtpsTmoleculargenetictestingusedin" rid-ob="figobrtpsTmoleculargenetictestingusedin">Table 1</a>).</div></li></ul><p>Molecular genetic testing approaches can include <b>serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Serial single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> may be considered in individuals with absence of SMARCA4 or SMARCB1 identified on tumor immunohistochemistry:</p><ul><li class="half_rhythm"><div><b>Absence of SMARCA4</b>. Sequence analysis and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>SMARCA4</i> may be performed first.</div></li><li class="half_rhythm"><div><b>Absence of SMARCB1.</b> Sequence analysis and <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> of <i>SMARCB1</i> may be performed first.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SMARCA4</i>, <i>SMARCB1</i>, and other genes of interest (see <a href="#rtps.Differential_Diagnosis">Differential Diagnosis</a>) may be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel provides the best opportunity to identify the genetic cause of the condition at the most reasonable cost while limiting identification of pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. 3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="rtps.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Rhabdoid Tumor Predisposition Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK469816/table/rtps.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rtps.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_2" style="text-align:left;vertical-align:middle;">Proportion of RTPS Attributed to Pathogenic Variants in This Gene</th><th id="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_3" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr><tr><th headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></th><th headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_3" id="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></th></tr></thead><tbody><tr><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMARCA4</i></td><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~5%-15%&#x000a0;<sup>5</sup></td><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">4/9 individuals&#x000a0;<sup>6,&#x000a0;7</sup></td><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">5/9 individuals&#x000a0;<sup>6,&#x000a0;7</sup></td></tr><tr><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMARCB1</i></td><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~85%-95%&#x000a0;<sup>8</sup></td><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~46%&#x000a0;<sup>6,&#x000a0;9</sup></td><td headers="hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_1_3 hd_h_rtps.T.molecular_genetic_testing_used_in_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">~54%&#x000a0;<sup>6,&#x000a0;9</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="rtps.TF.1.1"><p class="no_margin">See <a href="/books/NBK469816/#rtps.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="rtps.TF.1.2"><p class="no_margin">See <a href="#rtps.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="rtps.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="rtps.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include multiplex ligation-dependent probe amplification (MLPA) designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="rtps.TF.1.5"><p class="no_margin">In individuals with RTPS confirmed by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> molecular testing, a germline <i>SMARCA4</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified in 3/50 individuals [EU-RHAB &#x02012; Author, personal communication], 6/35 individuals [Authors, personal communication], and 8/192 individuals [T Holsten, unpublished].</p></div></dd><dt>6. </dt><dd><div id="rtps.TF.1.6"><p class="no_margin">EU-RHAB &#x02012; Author, personal communication</p></div></dd><dt>7. </dt><dd><div id="rtps.TF.1.7"><p class="no_margin"><a class="bk_pop" href="#rtps.REF.hasselblatt.2014.453">Hasselblatt et al [2014]</a></p></div></dd><dt>8. </dt><dd><div id="rtps.TF.1.8"><p class="no_margin">In individuals with RTPS confirmed by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> molecular testing, a germline <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was identified in 47/50 individuals [EU-RHAB &#x02012; Author, personal communication], 29/35 individuals [Author, personal communication], and 184/192 individuals [<a class="bk_pop" href="#rtps.REF.holsten.2017.iv18">Holsten et al 2017</a>].</p></div></dd><dt>9. </dt><dd><div id="rtps.TF.1.9"><p class="no_margin"><a class="bk_pop" href="#rtps.REF.bourdeaut.2011.31">Bourdeaut et al [2011]</a>, <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al [2014]</a></p></div></dd></dl></div></div></div></div></div><div id="rtps.Clinical_Characteristics"><h2 id="_rtps_Clinical_Characteristics_">Clinical Characteristics</h2><div id="rtps.Clinical_Description"><h3>Clinical Description</h3><p>Rhabdoid tumor predisposition syndrome (RTPS) is characterized by a markedly increased risk of developing rhabdoid tumors.</p><p>Rhabdoid tumors are rare and highly aggressive malignant tumors occurring predominantly in infants and children younger than age three years. The term rhabdoid is derived from the histologic resemblance of tumor cells to rhabdomyoblast. Rhabdoid tumors are characterized by heaps of cells with an eccentric nucleus and prominent nucleolus, abundant cytoplasm with eosinophilic inclusion bodies, and distinct cellular membranes. Immunohistochemically rhabdoid tumor cells are characterized by increased expression of vimentin (a nonspecific marker), epithelial membrane antigen (EMA), cytokeratins, and loss of SMARCB1 protein (a strong indicator for rhabdoid tumor).</p><p>As morphologic rhabdoid features may not be present in all rhabdoid tumor biopsies because of inter- and intratumoral heterogeneity, any small blue round cell tumor in infants and young children should be evaluated for absence of nuclear SMARCB1 staining.</p><p>Primary rhabdoid tumor locations include the following:</p><ul><li class="half_rhythm"><div>Central nervous system (atypical teratoid/rhabdoid tumor [AT/RT]; &#x0003e;50% are cerebellar)</div></li><li class="half_rhythm"><div>Head and neck, paravertebral muscles, liver, bladder, mediastinum, retroperitoneum, pelvis, and heart (extracranial malignant rhabdoid tumor [eMRT])</div></li><li class="half_rhythm"><div>Kidney (rhabdoid tumor of the kidney [RTK])</div></li><li class="half_rhythm"><div>Ovary (small-cell carcinoma of the ovary [SCCOHT] &#x02012; hypercalcemic type)</div></li></ul><p>Rhabdoid tumors have been reported in nearly all anatomic locations [<a class="bk_pop" href="#rtps.REF.brennan.2013.e329">Brennan et al 2013</a>, <a class="bk_pop" href="#rtps.REF.sredni.2015.49">Sredni &#x00026; Tomita 2015</a>, <a class="bk_pop" href="#rtps.REF.fr_hwald.2016a.764">Fr&#x000fc;hwald et al 2016a</a>].</p><p>Individuals with RTPS typically present before age 12 months with synchronous tumors that exhibit aggressive clinical behavior, often in one of the following clinical settings:</p><ul><li class="half_rhythm"><div>Prenatally detected synchronous rhabdoid tumors</div></li><li class="half_rhythm"><div>Infantile-onset or <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> rhabdoid tumor, presentingat median age of four to seven months (range: prenatally &#x02013; 60 months) (compared to individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> rhabdoid tumor: median age 13-30 months; range: age 1 day - 228 months) [<a class="bk_pop" href="#rtps.REF.bruggers.2011.1026">Bruggers et al 2011</a>, <a class="bk_pop" href="#rtps.REF.geller.2015.199">Geller et al 2015</a>, <a class="bk_pop" href="#rtps.REF.fr_hwald.b">Fr&#x000fc;hwald et al 2016b</a>]. Note: A bias toward increased molecular testing in younger individuals may confound the data.</div></li><li class="half_rhythm"><div>Synchronous (multiple primary) rhabdoid tumors. Individuals with RTPS have a higher incidence of multiple rhabdoid tumors [<a class="bk_pop" href="#rtps.REF.eaton.2011.7">Eaton et al 2011</a>]. 28% of patients with RTPS in the EU-RHAB Registry had synchronous tumors; eight individuals had AT/RT and eMRT, four individuals had AT/RT and RTK, and two individuals with <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> synchronous tumors had AT/RT, multiple eMRT, and RTK [<a class="bk_pop" href="#rtps.REF.fr_hwald.b">Fr&#x000fc;hwald et al 2016b</a>].</div></li><li class="half_rhythm"><div>Family history of rhabdoid tumor, cribriform neuroepithelial tumor (CRINET), and/or distinct combinations of rhabdoid tumor with one of the following: schwannoma, malignant peripheral nerve sheath tumor, meningioma, or CRINET [<a class="bk_pop" href="#rtps.REF.van_den_munckhof.2012.1">van den Munckhof et al 2012</a>]</div></li><li class="half_rhythm"><div>Family history of small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT) for <i>SMARCA4</i>-related RTPS (<a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>SMARCB1</i> pathogenic variants have not been reported in individuals with SCCOHT) [<a class="bk_pop" href="#rtps.REF.moessosnowska.2015.32">Moes-Sosnowska et al 2015</a>, <a class="bk_pop" href="#rtps.REF.witkowski.2017.395">Witkowski et al 2017</a>]</div></li><li class="half_rhythm"><div>Clinically aggressive rhabdoid tumor. Tumor progression at the time of follow up was identified in 91% of individuals with RTPS. Progression occurred while on chemotherapy in 58% of individuals with RTPS [<a class="bk_pop" href="#rtps.REF.sredni.2015.49">Sredni &#x00026; Tomita 2015</a>, EU-RHAB &#x02012; Author, personal communication].</div></li><li class="half_rhythm"><div>Rhabdoid tumor and <a class="def" href="/books/n/gene/glossary/def-item/syndromic/">syndromic</a> features suggestive of 22q11.2 distal <a class="def" href="/books/n/gene/glossary/def-item/deletion-syndrome/">deletion syndrome</a> (OMIM <a href="http://omim.org/entry/611867" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">611867</a>)</div></li></ul><p><b>Prognosis.</b> Individuals with RTPS potentially have a worse prognosis than those with a <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> rhabdoid tumor; although long-term survival has been reported in some [<a class="bk_pop" href="#rtps.REF.ammerlaan.2008.474">Ammerlaan et al 2008</a>, <a class="bk_pop" href="#rtps.REF.modena.2013.100">Modena et al 2013</a>, <a class="bk_pop" href="#rtps.REF.kordes.2014.919">Kordes et al 2014</a>, <a class="bk_pop" href="#rtps.REF.seeringer.2014b.429">Seeringer et al 2014b</a>].</p></div><div id="rtps.Phenotype_Correlations_by_Gene"><h3>Phenotype Correlations by Gene</h3><p><b><i>SMARCA4.</i></b> Small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT) has been reported in individuals with <i>SMARCA4-</i>related RTPS and has not been reported in individuals with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>SMARCB1</i> pathogenic variants<i>.</i></p></div><div id="rtps.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> have been identified.</p></div><div id="rtps.Penetrance"><h3>Penetrance</h3><p><b><i>SMARCA4</i>.</b> Most individuals with <i>SMARCA4-</i>related RTPS have inherited the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from an unaffected, healthy parent. In <i>SMARCA4-</i>related RTPS the <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> for rhabdoid tumor in the preceding generation of seven informative families was zero. However, in one family, two sibs with a <i>SMARCA4</i> pathogenic variant were both <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> [<a class="bk_pop" href="#rtps.REF.schneppenheim.2010.279">Schneppenheim et al 2010</a>, <a class="bk_pop" href="#rtps.REF.hasselblatt.2014.453">Hasselblatt et al 2014</a>].</p><p><b><i>SMARCB1.</i></b> There are reports of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a>. Rarely a <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is inherited from an unaffected parent or a parent with late-onset or undiagnosed RTPS [<a class="bk_pop" href="#rtps.REF.ammerlaan.2008.474">Ammerlaan et al 2008</a>]. Germline <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> accounts for at least half of the families with sibs <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by RTPS.</p></div><div id="rtps.Nomenclature"><h3>Nomenclature</h3><p>Rhabdoid tumor predisposition syndrome may also be referred to as <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> posterior fossa brain tumor syndrome.</p><p>Current data suggest the value of subgroup determination for diagnostic and therapeutic decision making [<a class="bk_pop" href="#rtps.REF.torchia.2015.569">Torchia et al 2015</a>, <a class="bk_pop" href="#rtps.REF.johann.2016.379">Johann et al 2016</a>]:</p><ul><li class="half_rhythm"><div><b>ATRT-TYR</b> is characterized by infratentorial location, younger age at diagnosis (&#x0003c;1year), and overexpression of the genes <i>TYR</i> and <i>MITF</i>.</div></li><li class="half_rhythm"><div>In the subgroup <b>ATRT-MYC</b> tumors are mostly supratentorial, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are older (age 4-5 years) at diagnosis, and the genes <i>MYC, HOTAIR</i>, and <i>HOX</i> are overexpressed.</div></li><li class="half_rhythm"><div>The subgroup <b>ATRT-SHH</b> tumor location may be infratentorial or supratentorial, diagnosis is between ages two and five years, and sonic hedgehog pathway genes are overexpressed.</div></li></ul><p>Note: <a class="bk_pop" href="#rtps.REF.torchia.2016.891">Torchia et al [2016]</a> presented data on three subgroups that was similar to the subgroups described by <a class="bk_pop" href="#rtps.REF.johann.2016.379">Johann et al [2016]</a>. A consensus on simplifying subgroup nomenclature is currently being sought.</p></div><div id="rtps.Prevalence"><h3>Prevalence</h3><p>Among newly diagnosed individuals with rhabdoid tumors, 25%-35% will have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SMARCB1</i> [<a class="bk_pop" href="#rtps.REF.bourdeaut.2011.31">Bourdeaut et al 2011</a>, <a class="bk_pop" href="#rtps.REF.eaton.2011.7">Eaton et al 2011</a>, <a class="bk_pop" href="#rtps.REF.hasselblatt.2014.453">Hasselblatt et al 2014</a>].</p><p>The incidence of rhabdoid tumors may be estimated according to the following data:</p><ul><li class="half_rhythm"><div>The age-standardized annual incidence rate is between five (extracranial rhabdoid tumors) and 8.1 per million (atypical teratoid/rhabdoid tumor) in children younger than age one year, and decreases to between 0.6 and 2.2 per million at ages one to four years [<a class="bk_pop" href="#rtps.REF.brennan.2013.e329">Brennan et al 2013</a>, <a class="bk_pop" href="#rtps.REF.fr_hwald.2016a.764">Fr&#x000fc;hwald et al 2016a</a>].</div></li><li class="half_rhythm"><div>In the US, annual incidence among children younger than age 15 is 0.89 per million for AT/RT, 0.32 per million for eMRT, and 0.19 per million for RTK [<a class="bk_pop" href="#rtps.REF.heck.2013.77">Heck et al 2013</a>].</div></li></ul></div></div><div id="rtps.Genetically_Related_Allelic_Disorde"><h2 id="_rtps_Genetically_Related_Allelic_Disorde_">Genetically Related (Allelic) Disorders</h2><p><a class="figpopup" href="/books/NBK469816/table/rtps.T.allelic_disorders/?report=objectonly" target="object" rid-figpopup="figrtpsTallelicdisorders" rid-ob="figobrtpsTallelicdisorders">Table 2</a> includes other phenotypes caused by <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>SMARCA4</i> or <i>SMARCB1</i>. Note: Rhabdoid tumors have not been observed in any of these phenotypes.</p><div id="rtps.T.allelic_disorders" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Allelic Disorders</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK469816/table/rtps.T.allelic_disorders/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rtps.T.allelic_disorders_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rtps.T.allelic_disorders_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_rtps.T.allelic_disorders_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Phenotype&#x000a0;<sup>1</sup></th></tr></thead><tbody><tr><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMARCA4</i></td><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/coffin-siris/">Coffin-Siris syndrome</a></td></tr><tr><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Intellectual disability disorder NOS&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_1" rowspan="5" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMARCB1</i></td><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/schwann/">Schwannomatosis</a></td></tr><tr><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Meningiomatosis (OMIM <a href="https://omim.org/entry/607174" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">607174</a>)</td></tr><tr><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/coffin-siris/">Coffin-Siris syndrome</a></td></tr><tr><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/nbs/">Nicolaides-Baraitser syndrome</a> (1 individual reported)&#x000a0;<sup>3</sup></td></tr><tr><td headers="hd_h_rtps.T.allelic_disorders_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;">Intellectual disability disorder NOS&#x000a0;<sup>4</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">NOS = not otherwise specified</p></div></dd><dt>1. </dt><dd><div id="rtps.TF.2.1"><p class="no_margin">See hyperlinked <i>GeneReview</i>, OMIM <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> entry, or cited reference for more information.</p></div></dd><dt>2. </dt><dd><div id="rtps.TF.2.2"><p class="no_margin"><a href="http://denovo-db.gs.washington.edu/denovo-db/QueryVariantServlet?searchBy=Gene&#x00026;target=SMARCA4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">denovo-db - <i>SMARCA4</i></a></p></div></dd><dt>3. </dt><dd><div id="rtps.TF.2.3"><p class="no_margin"><a class="bk_pop" href="#rtps.REF.wieczorek.2013.5121">Wieczorek et al [2013]</a></p></div></dd><dt>4. </dt><dd><div id="rtps.TF.2.4"><p class="no_margin"><a href="http://denovo-db.gs.washington.edu/denovo-db/QueryVariantServlet?searchBy=Gene&#x00026;target=SMARCB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">denovo-db - <i>SMARCB1</i></a></p></div></dd></dl></div></div></div></div><div id="rtps.Differential_Diagnosis"><h2 id="_rtps_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Sporadic tumors.</b> Demonstration of loss of the SMARCA4 or SMARCB1 protein (in tumor tissue) due to inactivation or loss of one <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> of <i>SMARCB1</i> or <i>SMARCA4</i> (tumor tissue and constitutional samples) may suggest the diagnosis of RTPS. For example, one individual with a constitutional <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of <i>SMARCB1</i> and an epithelioid sarcoma was reported by <a class="bk_pop" href="#rtps.REF.le_loarer.2014.475">Le Loarer et al [2014]</a>. The absence of a clinical and family history of rhabdoid tumor(s) distinguishes these individuals from those with RTPS.</p><p>Several other malignant tumors with somatic pathogenic variants of <i>SMARCA4</i> or <i>SMARCB1</i> have not yet been associated with <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants in <i>SMARCA4</i> or <i>SMARCB1</i> (see Molecular Genetics, <a href="#rtps.SMARCA4"><i>SMARCA4</i></a> and <a href="#rtps.SMARCB1"><i>SMARCB1</i></a>, <b>Cancer and benign tumors</b>).</p></div><div id="rtps.Management"><h2 id="_rtps_Management_">Management</h2><div id="rtps.Evaluations_Following_Initial_Diagn"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs of an individual diagnosed with rhabdoid tumor predisposition syndrome (RTPS), the following are recommended:</p><ul><li class="half_rhythm"><div>Refer individuals with RTPS who have not yet developed a rhabdoid tumor to a pediatric oncologist or tumor surveillance program.</div></li><li class="half_rhythm"><div>Consider consulting a radiologist, prior to the planning of therapy, to assist in the selection and review of subsequent imaging, to evaluate the size and location of the primary tumor, and to evaluate for the presence of synchronous tumors and/or metastases (whole-body MRI).</div></li><li class="half_rhythm"><div>For individuals with atypical teratoid/rhabdoid tumor (AT/RT), examine cerebrospinal fluid (CSF) and determine classification according to Chang staging [<a class="bk_pop" href="#rtps.REF.harisiadis.1977.833">Harisiadis &#x00026; Chang 1977</a>].</div></li><li class="half_rhythm"><div>Refer for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a>.</div></li></ul></div><div id="rtps.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p>Current data suggest the value of subgroup determination for diagnostic and therapeutic decision making [<a class="bk_pop" href="#rtps.REF.torchia.2015.569">Torchia et al 2015</a>, <a class="bk_pop" href="#rtps.REF.johann.2016.379">Johann et al 2016</a>]:</p><ul><li class="half_rhythm"><div><b>ATRT-TYR</b> is characterized by infratentorial location, younger age at diagnosis (&#x0003c;1year), and overexpression of the genes <i>TYR</i> and <i>MITF</i>.</div></li><li class="half_rhythm"><div>In the subgroup <b>ATRT-MYC</b> tumors are mostly supratentorial, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are older (age 4-5 years) at diagnosis, and the genes <i>MYC, HOTAIR</i>, and <i>HOX</i> are overexpressed.</div></li><li class="half_rhythm"><div>The subgroup <b>ATRT-SHH</b> tumor location may be infratentorial or supratentorial, diagnosis is between ages two and five years, and sonic hedgehog pathway genes are overexpressed.</div></li></ul><p>Note: <a class="bk_pop" href="#rtps.REF.torchia.2016.891">Torchia et al [2016]</a> presented data on three subgroups that was similar to the subgroups described by <a class="bk_pop" href="#rtps.REF.johann.2016.379">Johann et al [2016]</a>. A consensus on simplifying subgroup nomenclature is currently being sought.</p><p>Due to the rarity of RTPS, standards for management are evolving. Most individuals are treated by intensive multimodal therapeutic strategies, combining surgery, radiotherapy, and chemotherapy according to institutional preference:</p><ul><li class="half_rhythm"><div>The Children's Oncology Group has employed a combination of surgery, two cycles of induction chemotherapy (cisplatinum, cyclophosphamide, etoposide, vincristine, methotrexate), three cycles of high-dose chemotherapy with stem cell rescue (thiotepa, carboplatinum) as consolidation therapy, and radiotherapy according to age and stage [protocol ACNS0333 <a href="https://clinicaltrials.gov/ct2/results?cond=&#x00026;term=NCT00653068&#x00026;cntry1=&#x00026;state1=&#x00026;recrs=" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">clinicaltrials.gov</a><a href="https://doi.org/10.1093/neuonc/now065.08" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">, Reddy et al 2016</a>].</div></li><li class="half_rhythm"><div>The Dana Faber Consortium has tested combination therapy with surgery, radiotherapy, and chemotherapy (vincristine, dactinomycin, cyclophosphamide, cisplatinum, doxorubicin, temozolomide and intrathecal methotrexate, cytarabine, and hydrocortisone) [<a href="https://clinicaltrials.gov/ct2/results?cond=&#x00026;term=NCT00084838&#x00026;cntry1=&#x00026;state1=&#x00026;Search=Search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">clinicaltrials.gov</a>, <a class="bk_pop" href="#rtps.REF.chi.2009.385">Chi et al 2009</a>].</div></li><li class="half_rhythm"><div>The <a href="http://www.rhabdoid.de/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU-RHAB Registry</a> recommends using combination therapy for rhabdoid tumors of any location (e.g., AT/RT, rhabdoid tumor of the kidney [RTK], extracranial malignant RT [eMRT]) including gross total resection, conventional chemotherapy (vincristine, dactinomycin, cyclophosphamide, doxorubicin, ifosfamide, carboplatinum, etoposide), intrathecal methotrexate, and permissive use of high-dose chemotherapy with stem cell rescue (carboplatinum, thiotepa) and radiotherapy (in individuals age &#x0003e;18 months). The feasibility of intensive multimodal regimen even in the youngest individuals including those <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> by RTPS has been demonstrated [<a class="bk_pop" href="#rtps.REF.seeringer.2014a.143">Seeringer et al 2014a</a>, <a class="bk_pop" href="#rtps.REF.bartelheim.2016.1765">Bartelheim et al 2016</a>].</div></li><li class="half_rhythm"><div>The Canadian Brain Tumour Consortium retrospectively evaluated children diagnosed with rhabdoid tumors between 1995 and 2007. Among 40 individuals, 22 received conventional chemotherapy and 18 received high-dose chemotherapy (HDCT) regimens; 15 received adjuvant radiation. Notably, six of 12 long-term survivors never received any radiotherapy [<a class="bk_pop" href="#rtps.REF.lafaycousin.2012.353">Lafay-Cousin et al 2012</a>].</div></li><li class="half_rhythm"><div>Zaky et al evaluated the Head Start III experience for newly diagnosed patients with AT/RT. Between 2003 and 2009, 19 patients were treated with a combination of surgery and five courses of induction chemotherapy followed by consolidation with myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue and radiotherapy according to age and stage. In five patients toxicity-related deaths occurred; ten patients died due to disease progression. The three-year overall survivial (OS) and event-free survival rates were 26&#x000b1;10% and 21&#x000b1;9%, respectively [<a class="bk_pop" href="#rtps.REF.zaky.2014.95">Zaky et al 2014</a>].</div></li><li class="half_rhythm"><div>Schrey et al summarized HDCT data by an individual pooled data analysis of 12 manuscripts and 389 publications including prospective and retrospective studies focused on the treatment of children diagnosed with AT/RT. Data of 332 patients demonstrated an improved outcome in those treated with HDCT-SCR and radiotherapy [<a class="bk_pop" href="#rtps.REF.schrey.2016.81">Schrey et al 2016</a>].</div></li><li class="half_rhythm"><div>Fischer-Valuck evaluated data of 361 children diagnosed with AT/RT between 2004 and 2012. The five-year OS rate was 29.9%, and it was significantly higher for patients with localized disease treated with multimodal therapy (surgery, chemotherapy, and radiotherapy) with a five-year OS of 46.8%. Patients younger than age three years at diagnosis showed significantly worse OS (5-year OS 27.7%) compared to older patients (5-year OS 37.5%) and were also significantly less likely to receive multimodal therapy (specifically, the radiotherapy component). The authors suggest early radiotherapy as an important factor for long-term cure [<a class="bk_pop" href="#rtps.REF.fischervaluck.2017.682">Fischer-Valuck et al 2017</a>].</div></li></ul><p>Note: RTPS most commonly affects infants; therapy presents a rather complex challenge due to the vulnerability of infants. The use of aggressive multimodal treatment on the developing nervous system and other organ systems of a young individual may profoundly affect developmental (e.g., neurodevelopmental) outcome, and entail significant short- and long-term side effects. Intensive induction chemotherapy may often achieve good responses and individuals may proceed with radiotherapy or (tandem) high-dose chemotherapy (HDCT) followed by autologous stem cell support.</p><p>It remains to be determined whether a subgroup of children may be cured by surgery and chemotherapy alone, thus avoiding the potential severe side effects of radiotherapy to the developing brain.</p></div><div id="rtps.Prevention_of_Primary_Manifestation"><h3>Prevention of Primary Manifestations</h3><p>Prophylactic bilateral oophorectomy may be discussed with women with <i>SMARCA4-</i>related RTPS after childbearing because of the high risk of developing small-cell carcinoma of the ovary, hypercalcemic type (SCCOHT)<i>.</i></p></div><div id="rtps.Prevention_of_Secondary_Complicatio"><h3>Prevention of Secondary Complications</h3><p>The intensive multimodal treatment strategies required for clinically aggressive tumors in children with RTPS lead to a higher rate of secondary complications. Therapies and interventions which may prevent secondary complications include the following:</p><ul><li class="half_rhythm"><div>Consideration of risk-reducing treatment strategies (e.g., postpone or replace radiotherapy with HDCT or proton beam therapy; targeted therapy used concomitant with &#x02013; or before &#x02013; standard chemotherapy)</div></li><li class="half_rhythm"><div>Long-term or lifelong surveillance in RTPS survivors (see <a href="#rtps.Surveillance">Surveillance</a>)</div></li></ul></div><div id="rtps.Surveillance"><h3>Surveillance</h3><p>Surveillance guidelines for patients with RTPS have been provided by <a class="bk_pop" href="#rtps.REF.teplick.2011.285">Teplick et al [2011]</a> and <a class="bk_pop" href="#rtps.REF.foulkes.2017.e62">Foulkes et al [2017]</a>.</p><p><b>Birth to age one year.</b> Monthly physical and neurologic examination, head ultrasound, and abdominal and pelvic ultrasound are desirable. If not feasible, alternate guidelines for patients with:</p><ul><li class="half_rhythm"><div><b>AT/RT</b> are physical and neurologic examination, including head ultrasound monthly plus every two to three months abdominal and pelvic ultrasound as a minimum requirement. If fontanelle closes prematurely consider head MRI every two to three months.</div></li><li class="half_rhythm"><div><b>eMRT or RTK</b> are abdominal and pelvic plus head ultrasound examination monthly. If ultrasound is not sufficient consider MRI at least every two to three months for affected site and ultrasound for all other sites. Whole-body MRI is desirable but not universally available.</div></li></ul><p><b>Age one year to age four to five years</b></p><ul><li class="half_rhythm"><div><b>AT/RT.</b> Brain and total spine MRI examination every three months. If available whole-body MRI may be considered. Note: Whole-body MRI resolution may not be sufficent for brain MRI, which would then need to be performed separately.</div></li><li class="half_rhythm"><div><b>eMRT or RTK.</b> Abdominal and pelvic ultrasound examination or MRI every three months; alternatively, whole-body MRI</div></li></ul><p>After age four years the risk of developing a new rhabdoid tumor dramatically decreases [<a class="bk_pop" href="#rtps.REF.eaton.2011.7">Eaton et al 2011</a>]. It remains worthwhile, however, to screen individuals with RTPS for other manifestations (e.g., schwannomas, SCCOHT). A practical approach would include annual physical examination with targeted imaging for symptomatic areas (e.g., neurologic deficit, change in physical features, menstrual disturbances) and referral to a tumor predisposition clinic.</p><p>Note: Individuals diagnosed with <i>SMARCA4</i>-related SCCOHT should be screened by abdominal and pelvic ultrasound examination every six months.</p><div id="rtps.T.surveillance_used_in_individuals" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Surveillance Used in Individuals with Rhabdoid Tumor, Including Individuals with Rhabdoid Tumor Predisposition Syndrome</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK469816/table/rtps.T.surveillance_used_in_individuals/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rtps.T.surveillance_used_in_individuals_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_2" style="text-align:left;vertical-align:middle;">Organ</th><th id="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3" colspan="3" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Screening According to Type of Germline Alteration and Age</th></tr><tr><th headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3" id="hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Predicted <a class="def" href="/books/n/gene/glossary/def-item/inactivating/">inactivating</a> variant</th><th headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3" id="hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Missense<br />variant</th></tr></thead><tbody><tr><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_1" rowspan="4" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMARCB1-</i>related RTPS</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Brain</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age &#x0003c;1 yr</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 1 to 4-5 yrs</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">No screening /<br />very low risk</td></tr><tr><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Head ultrasound monthly &#x00026; abdominal, pelvic ultrasound every 1 (2-3) mos</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Brain, spine, &#x00026; whole-body MRI every 3 mos</td></tr><tr><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_2" rowspan="2" colspan="1" scope="row" style="text-align:left;vertical-align:middle;">Abdomen</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age &#x0003c;1 yr</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Age 1 to 4-5 yrs</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">No screening /<br />very low risk</td></tr><tr><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Abdominal, pelvic, &#x00026; head ultrasound monthly, alternatively MRI every 2-3 mos&#x000a0;<sup>1</sup></td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abdominal &#x00026; pelvic ultrasound or MRI every 3 mos</td></tr><tr><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMARCA4-</i>related RTPS</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Brain</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_2" colspan="3" rowspan="1" style="text-align:left;vertical-align:middle;">Insufficient data&#x000a0;<sup>2</sup></td></tr><tr><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Abdomen</td><td headers="hd_h_rtps.T.surveillance_used_in_individuals_1_1_1_3 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_1 hd_h_rtps.T.surveillance_used_in_individuals_1_1_2_2" colspan="3" rowspan="1" style="text-align:left;vertical-align:middle;">Insufficient data</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin"><a class="bk_pop" href="#rtps.REF.teplick.2011.285">Teplick et al [2011]</a>, <a class="bk_pop" href="#rtps.REF.foulkes.2017.e62">Foulkes et al [2017]</a></p></div></dd><dt>1. </dt><dd><div id="rtps.TF.3.1"><p class="no_margin">If ultrasound is not sufficient consider MRI at least every two to three months.</p></div></dd><dt>2. </dt><dd><div id="rtps.TF.3.2"><p class="no_margin">One in ten individuals with AT/RT had a <i>SMARCA4</i> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> detected</p></div></dd></dl></div></div></div></div><div id="rtps.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Limit exposure to DNA-damaging agents including radiation (e.g., x-ray, CT, external beam radiotherapy), tobacco, UV light, and chemotherapy to minimize the lifetime risk of developing late-onset secondary cancers. Imaging tests utilizing radioactive compounds should only be used if absolutely necessary for essential health care.</p></div><div id="rtps.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>If a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SMARCA4</i> or <i>SMARCB1</i> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of apparently asymptomatic older and younger sibs and other at-risk relatives is appropriate. Early detection of individuals who are <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for an <i>SMARCA4</i> or <i>SMARCB1</i> pathogenic variant allows prompt initiation of <a href="#rtps.Surveillance">surveillance</a>, treatment, and preventative measures.</p><p>See <a href="#rtps.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="rtps.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>The following clinical trials are currently recruiting unless indicated otherwise:</p><ul><li class="half_rhythm"><div>NCT02114229: Phase I/II trial of Alisertib as a Single Agent in Recurrent or Progressive Central Nervous System (CNS) Atypical Teratoid Rhabdoid Tumors (AT/RT) and Extra-CNS Malignant Rhabdoid Tumors (MRT) and in Combination Therapy in Newly Diagnosed AT/RT</div></li><li class="half_rhythm"><div>NCT02601937: Phase I trial of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects with Relapsed or Refractory INI1<i>-</i>Negative Tumors or Synovial Sarcoma</div></li><li class="half_rhythm"><div>NCT02601950: Phase II trial Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma</div></li><li class="half_rhythm"><div>NCT03213665: Phase II trial Pediatric MATCH: Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With <i>EZH2</i>, <i>SMARCB1</i>, or <i>SMARCA4</i> Gene Mutations (not recruiting)</div></li><li class="half_rhythm"><div>NCT01747876: Phase I, Multi-center, Open-label Study of LEE011 in Patients with Malignant Rhabdoid Tumors and Neuroblastoma [<a class="bk_pop" href="#rtps.REF.geoerger.2017.2433">Geoerger et al 2017</a>] (not recruiting)</div></li><li class="half_rhythm"><div>NCT02644460: Phase I trial, Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors (AflacST1501)</div></li></ul><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="rtps.Genetic_Counseling"><h2 id="_rtps_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="rtps.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Rhabdoid tumor predisposition syndrome (RTPS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="rtps.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm"><i>SMARCA4.</i> Most reported individuals diagnosed with <i>SMARCA4</i>-related RTPS inherited a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from an unaffected parent [<a class="bk_pop" href="#rtps.REF.hasselblatt.2014.453">Hasselblatt et al 2014</a>].</div></li><li class="half_rhythm"><div class="half_rhythm"><i>SMARCB1</i></div><ul><li class="half_rhythm"><div>The vast majority of individuals diagnosed with RTPS have the disorder as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al 2014</a>].</div></li><li class="half_rhythm"><div>In rare cases, individuals diagnosed with RTPS inherited a <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> from an unaffected parent.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm">Recommendations for the evaluation of parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., neither parent is known to have RTPS) include <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the parents for the <i>SMARCA4</i> or <i>SMARCB1</i> pathogenic variant identified in the proband.</div><div class="half_rhythm">Note: A phenotypically healthy parent with a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/germline-variant/">germline variant</a> should be offered surveillance as for sibs (see <a href="#rtps.Surveillance">Surveillance</a>) &#x02013; albeit at longer intervals as the risk of embryonal malignancies is very low. The type of late-occurring neoplasias for which <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parents may be at risk is not clear from current data.</div></li><li class="half_rhythm"><div class="half_rhythm">If the <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. Parental germline mosaicism in <i>SMARCB1</i>-related RTPS has been reported [<a class="bk_pop" href="#rtps.REF.s_venet.1999.2359">S&#x000e9;venet et al 1999</a>, <a class="bk_pop" href="#rtps.REF.bruggers.2011.1026">Bruggers et al 2011</a>, <a class="bk_pop" href="#rtps.REF.eaton.2011.7">Eaton et al 2011</a>, <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al 2014</a>, <a class="bk_pop" href="#rtps.REF.gigante.2016.123">Gigante et al 2016</a>]. The overall incidence of germline mosaicism in RTPS is unknown but is presumed to be low.</div></li><li class="half_rhythm"><div class="half_rhythm">The family history of most individuals with RTPS may appear to be negative because of failure to recognize the disorder in family members, reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> (highly likely in <i>SMARCA4</i>-related RTPS), or late onset in the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. Therefore, an apparently negative family history cannot be confirmed unless appropriate <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The risk of the sibs of a proband depends on the genetic status of the proband's parents:</p><ul><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> and/or known to have an <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%. However, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> appears to be incomplete (see <a href="#rtps.Penetrance">Penetrance</a>) and the types of RTPS-related tumors can vary among different members of the same family.</div></li><li class="half_rhythm"><div>If the parents have been tested for the <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and the pathogenic variant cannot be detected in the leukocyte (i.e., constitutional) DNA of either parent, the empiric <a class="def" href="/books/n/gene/glossary/def-item/recurrence-risk/">recurrence risk</a> to sibs is approximately 1% because of the theoretic possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> [<a class="bk_pop" href="#rtps.REF.bruggers.2011.1026">Bruggers et al 2011</a>, <a class="bk_pop" href="#rtps.REF.eaton.2011.7">Eaton et al 2011</a>, <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al 2014</a>, <a class="bk_pop" href="#rtps.REF.gigante.2016.123">Gigante et al 2016</a>].</div></li><li class="half_rhythm"><div>If the parents have not been tested for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> but are clinically unaffected, sibs are still presumed to be at increased risk for RTPS because of the possibility of reduced <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> in a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> parent or parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has a 50% chance of inheriting the pathogenic variant. However, <a class="def" href="/books/n/gene/glossary/def-item/penetrance/">penetrance</a> appears to be incomplete and the types of RTPS-related tumors can vary among different members of the same family.</p><p><b>Other family members.</b> The risk to other family members depends on the status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent has a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, his or her family members may be at risk.</p></div><div id="rtps.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#rtps.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Genetic cancer risk assessment and counseling.</b> For a comprehensive description of the medical, psychosocial, and ethical ramifications of identifying at-risk individuals through cancer risk assessment with or without <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>, see <a href="http://www.cancer.gov/about-cancer/causes-prevention/genetics/risk-assessment-pdq" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Cancer Genetics Risk Assessment and Counseling &#x02013; for health professionals</a> (part of PDQ<sup>&#x000ae;</sup>, National Cancer Institute).</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells but also from tumor tissue) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="rtps.Prenatal_Testing_and_Preimplantatio"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>High-risk pregnancies (i.e., those with a family history of RTPS).</b> Once the <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Note: Rhabdoid tumors associated with RTPS may develop before birth; therefore, if the <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the fetus, high-level ultrasound examination may be used to detect and identify prenatal manifestations of a primary tumor.</p><p><b>Low-risk pregnancies (i.e., those without a known family history of RTPS).</b> If a primary tumor is detected on general prenatal ultrasound screening (and confirmed with high-level ultrasound), prenatal testing for a <i>SMARCA4</i> or <i>SMARCB1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> may be discussed. Note: Specific treatment for this patient group is currently not available; interventions may be discussed, but long-term survival has been also recorded in some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals [<a class="bk_pop" href="#rtps.REF.seeringer.2014b.429">Seeringer et al 2014b</a>].</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="rtps.Resources"><h2 id="_rtps_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>American Cancer Society (ACS)</b></div><div>250 Williams Street Northwest</div><div>Atlanta GA 30303</div><div><b>Phone:</b> 800-227-2345 (toll-free 24/7); 866-228-4327 (toll-free 24/7 TTY)</div><div><a href="http://www.cancer.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancer.org</a></div></li><li class="half_rhythm"><div><b>American Childhood Cancer Organization (ACCO)</b></div><div>6868 Distribution Drive</div><div>Beltsville MD 20705</div><div><b>Phone:</b> 855-858-2226 (toll-free); 301-962-3520</div><div><b>Fax:</b> 301-962-3521</div><div><b>Email:</b> staff@acco.org</div><div><a href="http://www.acco.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.acco.org</a></div></li><li class="half_rhythm"><div><b>CancerCare</b></div><div>275 Seventh Avenue</div><div>22nd Floor</div><div>New York NY 10001</div><div><b>Phone:</b> 800-813-4673 (toll-free); 212-712-8400 (administrative)</div><div><b>Fax:</b> 212-712-8495</div><div><b>Email:</b> info@cancercare.org</div><div><a href="http://www.cancercare.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.cancercare.org</a></div></li><li class="half_rhythm"><div><b>National Brain Tumor Society</b></div><div>124 Watertown Street</div><div>Suite 2D</div><div>Watertown MA 02472</div><div><b>Phone:</b> 800-770-8287 (toll-free); 617-924-9997; 800-934-2873 (Toll-free Patient Services)</div><div><b>Fax:</b> 617-924-9998</div><div><b>Email:</b> info@braintumor.org</div><div><a href="http://www.braintumor.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.braintumor.org</a></div></li><li class="half_rhythm"><div><b>European Rhabdoid Registry (EU-RHAB)</b></div><div>Stenglingstr. 2.</div><div>Augsburg 86156</div><div>Germany</div><div><b>Phone:</b> 00498214004342</div><div><b>Fax:</b> 0049821400174243</div><div><b>Email:</b> eurhab@klinikum-augsburg.de</div><div><a href="http://www.rhabdoid.de/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rhabdoid.de</a></div></li></ul></div><div id="rtps.Molecular_Genetics"><h2 id="_rtps_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="rtps.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Rhabdoid Tumor Predisposition Syndrome: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK469816/table/rtps.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rtps.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_rtps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_rtps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_rtps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_rtps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_rtps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_rtps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_rtps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6597" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SMARCA4</i></a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6597" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P51532" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Transcription activator BRG1</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SMARCA4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMARCA4 database</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SMARCA4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMARCA4</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SMARCA4[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMARCA4</a></td></tr><tr><td headers="hd_b_rtps.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/6598" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SMARCB1</i></a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=6598" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q11<wbr style="display:inline-block"></wbr>​.23</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/Q12824" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SMARCB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMARCB1 database</a><br /><a href="https://www.uke.de/dateien/kliniken/paediatrische-haematologie-und-onkologie/dokumente/smarcb1/smarcb1_data_uke_2009-11-26.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UKE Hamburg SMARCB1 database</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SMARCB1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMARCB1</a></td><td headers="hd_b_rtps.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SMARCB1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SMARCB1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="rtps.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="rtps.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Rhabdoid Tumor Predisposition Syndrome (<a href="/omim/601607,603254,609322,613325" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK469816/table/rtps.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__rtps.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/601607" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">601607</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY B, MEMBER 1; SMARCB1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/603254" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">603254</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SWI/SNF-RELATED, MATRIX-ASSOCIATED, ACTIN-DEPENDENT REGULATOR OF CHROMATIN, SUBFAMILY A, MEMBER 4; SMARCA4</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609322" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609322</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RHABDOID TUMOR PREDISPOSITION SYNDROME 1; RTPS1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613325" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613325</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">RHABDOID TUMOR PREDISPOSITION SYNDROME 2; RTPS2</td></tr></tbody></table></div></div><div id="rtps.Molecular_Genetic_Pathogenesis"><h3>Molecular Genetic Pathogenesis</h3><p>Rhabdoid tumor predisposition syndrome is typically characterized by <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants that predict inactivation of <i>SMARCA4</i> (very rarely) or <i>SMARCB1</i> (more commonly).</p><p>SMARCA4 with its ATPase activity is the catalytic subunit and SMARCB1 is a core protein of the SWI/SNF chromatin remodeling complex. SWI/SNF interacts with various pathways (p16-Rb pathway, Wnt-&#x003b2;-catenin pathway, sonic hedgehog signal pathway, polycomb pathway, MYCC, Aurora A) and affects many essential biological functions in developing organs, including cell cycle and cell differentiation, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> expression, DNA repair [<a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al 2014</a>, <a class="bk_pop" href="#rtps.REF.kim.2014.365">Kim &#x00026; Roberts 2014</a>, <a class="bk_pop" href="#rtps.REF.kohashi.2017.547">Kohashi &#x00026; Oda 2017</a>].</p><p>Although unrelated to RTPS, somatic variants are known to occur in other genes encoding multiple members of the SWI/SNF chromatin remodeling complex (reviewed in <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al [2014]</a>).</p><div id="rtps.SMARCA4"><h4><i>SMARCA4</i></h4><p><b>Gene structure.</b> Multiple transcript variants encoding different <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> have been identified; for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and transcript information, see <a href="/books/NBK469816/#rtps.molgen.TA">Table A</a>, <b>Gene</b>.</p><p>By convention, pathogenic variants are numbered based on the sequence of the transcript encoding the longest isoform, which is transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001128849.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001128849.1</a>, comprising 36 exons.</p><p><b>Pathogenic variants.</b> Reported pathogenic variants include <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> and intragenic deletions that predict inactivation (see <a href="/books/NBK469816/#rtps.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>HGMD</b>). To date, only a single <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>SMARCA4</i> variant has been reported in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual and his unaffected father [<a class="bk_pop" href="#rtps.REF.hasselblatt.2014.453">Hasselblatt et al 2014</a>].</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_001128849.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001128849.1</a> encodes the 1679-amino acid isoform A (<a href="https://www.ncbi.nlm.nih.gov/protein/NP_001122321.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001122321.1</a>). SMARCA4, known as transcription activator BRG1, is a catalytic component of the ATP-dependent SWI/SNF chromatin remodeling complex (hSWI/SNF/BAF) and is essential for the transcriptional activation of genes. For a detailed summary of transcript and protein isoform information, see <a href="/books/NBK469816/#rtps.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#rtps.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</a>.</p><p><b>Cancer and benign tumors.</b> Sporadic rhabdoid tumors may occur as single tumors in the absence of any other findings of RTPS and harbor somatic (acquired) <i>SMARCA4</i> variants that are not present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> [<a class="bk_pop" href="#rtps.REF.schneppenheim.2010.279">Schneppenheim et al 2010</a>, <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al 2014</a>]. In these circumstances predisposition to these tumors is not heritable.</p><p>The routine application of immunohistochemistry to all neural tumors has identified other tumors with loss of SMARCA4 expression (reviewed in <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al [2014]</a> and <a class="bk_pop" href="#rtps.REF.margol.2014.358">Margol &#x00026; Judkins [2014]</a>). Whether SMARCA4 plays a role in development of these tumors is not known.</p></div><div id="rtps.SMARCB1"><h4><i>SMARCB1</i></h4><p><b>Gene structure.</b>
<i>SMARCB1</i> comprises nine exons, produces a 1.749-bp transcript variant 1 (<a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_003073.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_003073.3</a>), and encodes the isoform A.</p><p><b>Pathogenic variants.</b> Reported pathogenic variants predict inactivation (<a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, whole- and partial-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>); <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al [2014]</a> summarized the types and percentages of <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants identified in a large cohort of individuals with rhabdoid tumor.</p><p>Common <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> pathogenic variants of <i>SMARCB1</i> reported in rhabdoid tumors may be found in <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a>-specific databases and HGMD (see <a href="/books/NBK469816/#rtps.molgen.TA">Table A</a>, <b>Locus-Specific Databases</b> and <b>HGMD</b>).</p><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The SMARCB1 protein contains 385 amino acids (<a href="https://www.ncbi.nlm.nih.gov/protein/NP_003064.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_003064.2</a>) and is a core component of the ATP-dependent SWI/SNF chromatin remodeling complex (hSWI/SNF/BAF). It plays important roles in cell proliferation, differentiation, cellular antiviral activities, and inhibition of tumor formation.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> See <a href="#rtps.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</a>.</p><p><b>Cancer and benign tumors.</b> Sporadic rhabdoid tumors may occur as single tumors in the absence of any other findings of RTPS and harbor somatic (acquired) <i>SMARCB1</i> variants that are not present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> [<a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al 2014</a>]. In these circumstances predisposition to these tumors is not heritable.</p><p>The routine application of immunohistochemistry to all neural tumors has identified other tumors with loss of SMARCB1 expression (reviewed in <a class="bk_pop" href="#rtps.REF.biegel.2014.350">Biegel et al [2014]</a> and <a class="bk_pop" href="#rtps.REF.margol.2014.358">Margol &#x00026; Judkins [2014]</a>). Whether SMARCB1 plays a role in development of these tumors is not known.</p></div></div></div><div id="rtps.References"><h2 id="_rtps_References_">References</h2><div id="rtps.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.ammerlaan.2008.474">Ammerlaan AC, Ararou A, Houben MP, Baas F, Tijssen CC, Teepen JL, Wesseling P, Hulsebos TJ. Long-term survival and transmission of INI1-mutation via nonpenetrant males in a family with rhabdoid tumour predisposition syndrome. <span><span class="ref-journal">Br J Cancer. </span>2008;<span class="ref-vol">98</span>:474–9.</span> [<a href="/pmc/articles/PMC2361463/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2361463</span></a>] [<a href="/pubmed/18087273" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18087273</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.bartelheim.2016.1765">Bartelheim K, Nemes K, Seeringer A, Kerl K, Buechner J, Boos J, Graf N, D&#x000fc;rken M, Gerss J, Hasselblatt M, Kortmann RD, Teichert von Luettichau I, Nagel I, Nygaard R, Oyen F, Quiroga E, Schlegel PG, Schmid I, Schneppenheim R, Siebert R, Solano-Paez P, Timmermann B, Warmuth-Metz M, Fr&#x000fc;hwald MC. Improved 6-year overall survival in AT/RT - results of the registry study Rhabdoid 2007. <span><span class="ref-journal">Cancer Med. </span>2016;<span class="ref-vol">5</span>:1765–75.</span> [<a href="/pmc/articles/PMC4884635/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4884635</span></a>] [<a href="/pubmed/27228363" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27228363</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.biegel.2014.350">Biegel JA, Busse TM, Weissman BE. SWI/SNF chromatin remodeling complexes and cancer. <span><span class="ref-journal">Am J Med Genet C Semin Med Genet. </span>2014;<span class="ref-vol">166C</span>:350–66.</span> [<a href="/pmc/articles/PMC4516040/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4516040</span></a>] [<a href="/pubmed/25169151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25169151</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.bourdeaut.2011.31">Bourdeaut F, Lequin D, Brugi&#x000e8;res L, Reynaud S, Dufour C, Doz F, Andr&#x000e9; N, Stephan JL, P&#x000e9;rel Y, Oberlin O, Orbach D, Bergeron C, Rialland X, Fr&#x000e9;neaux P, Ranchere D, Figarella-Branger D, Audry G, Puget S, Evans DG, Pinas JC, Capra V, Mosseri V, Coupier I, Gauthier-Villars M, Pierron G, Delattre O. Frequent hSNF5/INI1 germline mutations in patients with rhabdoid tumor. <span><span class="ref-journal">Clin Cancer Res. </span>2011;<span class="ref-vol">17</span>:31–8.</span> [<a href="/pubmed/21208904" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21208904</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.brennan.2013.e329">Brennan B, Stiller C, Bourdeaut F. Extracranial rhabdoid tumours: what we have learned so far and future directions. <span><span class="ref-journal">Lancet Oncol. </span>2013;<span class="ref-vol">14</span>:e329–36.</span> [<a href="/pubmed/23816299" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23816299</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.bruggers.2011.1026">Bruggers CS, Bleyl SB, Pysher T, Barnette P, Afify Z, Walker M, Biegel JA. Clinicopathologic comparison of familial versus sporadic atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2011;<span class="ref-vol">56</span>:1026–31.</span> [<a href="/pmc/articles/PMC3210729/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3210729</span></a>] [<a href="/pubmed/20848638" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20848638</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.chi.2009.385">Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE, Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L, Ullrich NJ, Kieran MW. Intensive multimodality treatment for children with newly diagnosed CNS atypical teratoid rhabdoid tumor. <span><span class="ref-journal">J Clin Oncol. </span>2009;<span class="ref-vol">27</span>:385–9.</span> [<a href="/pmc/articles/PMC2645855/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2645855</span></a>] [<a href="/pubmed/19064966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19064966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.eaton.2011.7">Eaton KW, Tooke LS, Wainwright LM, Judkins AR, Biegel JA. Spectrum of SMARCB1/INI1 mutations in familial and sporadic rhabdoid tumors. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2011;<span class="ref-vol">56</span>:7–15.</span> [<a href="/pmc/articles/PMC3086793/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3086793</span></a>] [<a href="/pubmed/21108436" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21108436</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.fischervaluck.2017.682">Fischer-Valuck BW, Chen I, Srivastava AJ, Floberg JM, Rao YJ, King AA, Shinohara ET, Perkins SM. Assessment of the treatment approach and survival outcomes in a modern cohort of patients with atypical teratoid rhabdoid tumors using the National Cancer Database. <span><span class="ref-journal">Cancer. </span>2017;<span class="ref-vol">123</span>:682–7.</span> [<a href="/pubmed/27861763" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27861763</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.foulkes.2017.e62">Foulkes WD, Kamihara J, Evans DGR, Brugi&#x000e8;res L, Bourdeaut F, Molenaar JJ, Walsh MF, Brodeur GM, Diller L. Cancer surveillance in Gorlin syndrome and rhabdoid tumor predisposition syndrome. <span><span class="ref-journal">Clin Cancer Res. </span>2017;<span class="ref-vol">23</span>:e62–e67.</span> [<a href="/pubmed/28620006" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28620006</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.fr_hwald.2016a.764">Fr&#x000fc;hwald MC, Biegel JA, Bourdeaut F, Roberts CW, Chi SN. Atypical teratoid/rhabdoid tumors-current concepts, advances in biology, and potential future therapies. <span><span class="ref-journal">Neuro Oncol. </span>2016a;<span class="ref-vol">18</span>:764–78.</span> [<a href="/pmc/articles/PMC4864253/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4864253</span></a>] [<a href="/pubmed/26755072" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26755072</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.fr_hwald.b">Fr&#x000fc;hwald MC, Zlatic M, Kachanov D, Nemes K, Clement N, Hasselblatt M, Shamanskaya T, Varfolomeeva S, Schneppenheim R, Siebert R, Leuschner I, Gerss J, Bourdeaut F. Congenital rhabdoid tumors &#x02013; a retrospective international series demonstrates dismal outcome but no futility of therapy. Abstract. Dublin, Ireland: 48<sup>th</sup> Congress of the International Society of Paediatric Oncology (SIOP). 2016b.</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.geller.2015.199">Geller JI, Roth JJ, Biegel JA. Biology and treatment of rhabdoid tumor. <span><span class="ref-journal">Crit Rev Oncog. </span>2015;<span class="ref-vol">20</span>:199–216.</span> [<a href="/pmc/articles/PMC6087667/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6087667</span></a>] [<a href="/pubmed/26349416" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26349416</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.geoerger.2017.2433">Geoerger B, Bourdeaut F, DuBois SG, Fischer M, Geller JI, Gottardo NG, Marabelle A, Pearson ADJ, Modak S, Cash T, Robinson GW, Motta M, Matano A, Bhansali SG, Dobson JR, Parasuraman S, Chi SN. A Phase I study of the CDK4/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. <span><span class="ref-journal">Clin Cancer Res. </span>2017;<span class="ref-vol">23</span>:2433–41.</span> [<a href="/pubmed/28432176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28432176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.gigante.2016.123">Gigante L, Paganini I, Frontali M, Ciabattoni S, Sangiuolo FC, Papi L. Rhabdoid tumor predisposition syndrome caused by SMARCB1 constitutional deletion: prenatal detection of new case of recurrence in siblings due to gonadal mosaicism. <span><span class="ref-journal">Fam Cancer. </span>2016;<span class="ref-vol">15</span>:123–6.</span> [<a href="/pubmed/26342593" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26342593</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.harisiadis.1977.833">Harisiadis L, Chang CH. Medulloblastoma in children: a correlation between staging and results of treatment. <span><span class="ref-journal">Int J Radiat Oncol Biol Phys. </span>1977;<span class="ref-vol">2</span>:833–41.</span> [<a href="/pubmed/597384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 597384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.hasselblatt.2014.453">Hasselblatt M, Nagel I, Oyen F, Bartelheim K, Russell RB, Sch&#x000fc;ller U, Junckerstorff R, Rosenblum M, Alassiri AH, Rossi S, Schmid I, Gottardo NG, Toledano H, Viscardi E, Balbin M, Witkowski L, Lu Q, Betts MJ, Foulkes WD, Siebert R, Fr&#x000fc;hwald MC, Schneppenheim R. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis. <span><span class="ref-journal">Acta Neuropathol. </span>2014;<span class="ref-vol">128</span>:453–6.</span> [<a href="/pubmed/25060813" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25060813</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.heck.2013.77">Heck JE, Lombardi CA, Cockburn M, Meyers TJ, Wilhelm M, Ritz B. Epidemiology of rhabdoid tumors of early childhood. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2013;<span class="ref-vol">60</span>:77–81.</span> [<a href="/pmc/articles/PMC3399923/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3399923</span></a>] [<a href="/pubmed/22434719" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22434719</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.holsten.2017.iv18">Holsten T, Hasselblatt M, Kordes U, Siebert R, Schneppenheim R, Fr&#x000fc;hwald M, Sch&#x000fc;ller U. Gene-02. Germline mutations within the SWI/SNF complex predict patients' age of onset and type of disease. <span><span class="ref-journal">Neuro Oncol. </span>2017;<span class="ref-vol">19</span>:iv18.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.johann.2016.379">Johann PD, Erkek S, Zapatka M, Kerl K, Buchhalter I, Hovestadt V, Jones DT, Sturm D, Hermann C, Segura Wang M, Korshunov A, Rhyzova M, Gr&#x000f6;bner S, Brabetz S, Chavez L, Bens S, Gr&#x000f6;schel S, Kratochwil F, Wittmann A, Sieber L, Ge&#x000f6;rg C, Wolf S, Beck K, Oyen F, Capper D, van Sluis P, Volckmann R, Koster J, Versteeg R, von Deimling A, Milde T, Witt O, Kulozik AE, Ebinger M, Shalaby T, Grotzer M, Sumerauer D, Zamecnik J, Mora J, Jabado N, Taylor MD, Huang A, Aronica E, Bertoni A, Radlwimmer B, Pietsch T, Sch&#x000fc;ller U, Schneppenheim R, Northcott PA, Korbel JO, Siebert R, Fr&#x000fc;hwald MC, Lichter P, Eils R, Gajjar A, Hasselblatt M, Pfister SM, Kool M. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. <span><span class="ref-journal">Cancer Cell. </span>2016;<span class="ref-vol">29</span>:379–93.</span> [<a href="/pubmed/26923874" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26923874</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.kim.2014.365">Kim KH, Roberts CW. Mechanisms by which SMARCB1 loss drives rhabdoid tumor growth. <span><span class="ref-journal">Cancer Genet. </span>2014;<span class="ref-vol">207</span>:365–72.</span> [<a href="/pmc/articles/PMC4195815/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4195815</span></a>] [<a href="/pubmed/24853101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24853101</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.kohashi.2017.547">Kohashi K, Oda Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. <span><span class="ref-journal">Cancer Sci. </span>2017;<span class="ref-vol">108</span>:547–52.</span> [<a href="/pmc/articles/PMC5406539/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5406539</span></a>] [<a href="/pubmed/28109176" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28109176</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.kordes.2014.919">Kordes U, Bartelheim K, Modena P, Massimino M, Biassoni V, Reinhard H, Hasselblatt M, Schneppenheim R, Fr&#x000fc;hwald MC. Favorable outcome of patients affected by rhabdoid tumors due to rhabdoid tumor predisposition syndrome (RTPS). <span><span class="ref-journal">Pediatr Blood Cancer. </span>2014;<span class="ref-vol">61</span>:919–21.</span> [<a href="/pubmed/24123847" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24123847</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.lafaycousin.2012.353">Lafay-Cousin L, Hawkins C, Carret AS, Johnston D, Zelcer S, Wilson B, Jabado N, Scheinemann K, Eisenstat D, Fryer C, Fleming A, Mpofu C, Larouche V, Strother D, Bouffet E, Huang A. Central nervous system atypical teratoid rhabdoid tumours: the Canadian Paediatric Brain Tumour Consortium experience. <span><span class="ref-journal">Eur J Cancer. </span>2012;<span class="ref-vol">48</span>:353–9.</span> [<a href="/pubmed/22023887" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22023887</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.le_loarer.2014.475">Le Loarer F, Zhang L, Fletcher CD, Ribeiro A, Singer S, Italiano A, Neuville A, Houlier A, Chibon F, Coindre JM, Antonescu CR. Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. <span><span class="ref-journal">Genes Chromosomes Cancer. </span>2014;<span class="ref-vol">53</span>:475–86.</span> [<a href="/pmc/articles/PMC4226650/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4226650</span></a>] [<a href="/pubmed/24585572" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24585572</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.margol.2014.358">Margol AS, Judkins AR. Pathology and diagnosis of SMARCB1-deficient tumors. <span><span class="ref-journal">Cancer Genet. </span>2014;<span class="ref-vol">207</span>:358–64.</span> [<a href="/pubmed/25246033" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25246033</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.modena.2013.100">Modena P, Sardi I, Brenca M, Giunti L, Buccoliero AM, Pollo B, Biassoni V, Genitori L, Antonelli M, Maestro R, Giangaspero F, Massimino M. Case report: long-term survival of an infant syndromic patient affected by atypical teratoid-rhabdoid tumor. <span><span class="ref-journal">BMC Cancer. </span>2013;<span class="ref-vol">13</span>:100.</span> [<a href="/pmc/articles/PMC3600022/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3600022</span></a>] [<a href="/pubmed/23510391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23510391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.moessosnowska.2015.32">Moes-Sosnowska J, Szafron L, Nowakowska D, Dansonka-Mieszkowska A, Budzilowska A, Konopka B, Plisiecka-Halasa J, Podgorska A, Rzepecka IK, Kupryjanczyk J. Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2015;<span class="ref-vol">10</span>:32.</span> [<a href="/pmc/articles/PMC4365965/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4365965</span></a>] [<a href="/pubmed/25886974" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25886974</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.schneppenheim.2010.279">Schneppenheim R, Fr&#x000fc;hwald MC, Gesk S, Hasselblatt M, Jeibmann A, Kordes U, Kreuz M, Leuschner I, Martin Subero JI, Obser T, Oyen F, Vater I, Siebert R. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. <span><span class="ref-journal">Am J Hum Genet. </span>2010;<span class="ref-vol">86</span>:279–84.</span> [<a href="/pmc/articles/PMC2820190/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2820190</span></a>] [<a href="/pubmed/20137775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20137775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.schrey.2016.81">Schrey D, Carceller Lech&#x000f3;n F, Malietzis G, Moreno L, Dufour C, Chi S, Lafay-Cousin L, von Hoff K, Athanasiou T, Marshall LV, Zacharoulis S. Multimodal therapy in children and adolescents with newly diagnosed atypical teratoid rhabdoid tumor: individual pooled data analysis and review of the literature. <span><span class="ref-journal">J Neurooncol. </span>2016;<span class="ref-vol">126</span>:81–90.</span> [<a href="/pubmed/26608522" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26608522</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.seeringer.2014a.143">Seeringer A, Bartelheim K, Kerl K, Hasselblatt M, Leuschner I, Rutkowski S, Timmermann B, Kortmann RD, Koscielniak E, Schneppenheim R, Warmuth-Metz M, Gerss J, Siebert R, Graf N, Boos J, Fr&#x000fc;hwald MC. Feasibility of intensive multimodal therapy in infants affected by rhabdoid tumors - experience of the EU-RHAB registry. <span><span class="ref-journal">Klin Padiatr. </span>2014a;<span class="ref-vol">226</span>:143–8.</span> [<a href="/pubmed/24633978" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24633978</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.seeringer.2014b.429">Seeringer A, Reinhard H, Hasselblatt M, Schneppenheim R, Siebert R, Bartelheim K, Leuschner I, Fr&#x000fc;hwald MC. Synchronous congenital malignant rhabdoid tumor of the orbit and atypical teratoid/rhabdoid tumor--feasibility and efficacy of multimodal therapy in a long-term survivor. <span><span class="ref-journal">Cancer Genet. </span>2014b;<span class="ref-vol">207</span>:429–33.</span> [<a href="/pubmed/25262118" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25262118</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.s_venet.1999.2359">S&#x000e9;venet N, Lellouch-Tubiana A, Schofield D, Hoang-Xuan K, Gessler M, Birnbaum D, Jeanpierre C, Jouvet A, Delattre O. Spectrum of hSNF5/INI1 somatic mutations in human cancer and genotype-phenotype correlations. <span><span class="ref-journal">Hum Mol Genet. </span>1999;<span class="ref-vol">8</span>:2359–68.</span> [<a href="/pubmed/10556283" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10556283</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.sredni.2015.49">Sredni ST, Tomita T. Rhabdoid tumor predisposition syndrome. <span><span class="ref-journal">Pediatr Dev Pathol. </span>2015;<span class="ref-vol">18</span>:49–58.</span> [<a href="/pubmed/25494491" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25494491</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.teplick.2011.285">Teplick A, Kowalski M, Biegel JA, Nichols KE. Educational paper: screening in cancer predisposition syndromes: guidelines for the general pediatrician. <span><span class="ref-journal">Eur J Pediatr. </span>2011;<span class="ref-vol">170</span>:285–94.</span> [<a href="/pmc/articles/PMC3086787/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3086787</span></a>] [<a href="/pubmed/21210147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21210147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.torchia.2016.891">Torchia J, Golbourn B, Feng S, Ho KC, Sin-Chan P, Vasiljevic A, Norman JD, Guilhamon P, Garzia L, Agamez NR, Lu M, Chan TS, Picard D, de Antonellis P, Khuong-Quang DA, Planello AC, Zeller C, Barsyte-Lovejoy D, Lafay-Cousin L, Letourneau L, Bourgey M, Yu M, Gendoo DM, Dzamba M, Barszczyk M, Medina T, Riemenschneider AN, Morrissy AS, Ra YS, Ramaswamy V, Remke M, Dunham CP, Yip S, Ng HK, Lu JQ, Mehta V, Albrecht S, Pimentel J, Chan JA, Somers GR, Faria CC, Roque L, Fouladi M, Hoffman LM, Moore AS, Wang Y, Choi SA, Hansford JR, Catchpoole D, Birks DK, Foreman NK, Strother D, Klekner A, Bogn&#x000e1;r L, Garami M, Hauser P, Hortob&#x000e1;gyi T, Wilson B, Hukin J, Carret AS, Van Meter TE, Hwang EI, Gajjar A, Chiou SH, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheinemann K, Fleming AJ, Johnston DL, Michaud J, Zelcer S, Hammond R, Afzal S, Ramsay DA, Sirachainan N, Hongeng S, Larbcharoensub N, Grundy RG, Lulla RR, Fangusaro JR, Druker H, Bartels U, Grant R, Malkin D, McGlade CJ, Nicolaides T, Tihan T, Phillips J, Majewski J, Montpetit A, Bourque G, Bader GD, Reddy AT, Gillespie GY, Warmuth-Metz M, Rutkowski S, Tabori U, Lupien M, Brudno M, Sch&#x000fc;ller U, Pietsch T, Judkins AR, Hawkins CE, Bouffet E, Kim SK, Dirks PB, Taylor MD, Erdreich-Epstein A, Arrowsmith CH, De Carvalho DD, Rutka JT, Jabado N, Huang A. Integrated (epi)-genomic analyses identify subgroup-specific therapeutic targets in CNS rhabdoid tumors. <span><span class="ref-journal">Cancer Cell. </span>2016;<span class="ref-vol">30</span>:891–908.</span> [<a href="/pmc/articles/PMC5500911/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5500911</span></a>] [<a href="/pubmed/27960086" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27960086</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.torchia.2015.569">Torchia J, Picard D, Lafay-Cousin L, Hawkins CE, Kim SK, Letourneau L, Ra YS, Ho KC, Chan TS, Sin-Chan P, Dunham CP, Yip S, Ng HK, Lu JQ, Albrecht S, Pimentel J, Chan JA, Somers GR, Zielenska M, Faria CC, Roque L, Baskin B, Birks D, Foreman N, Strother D, Klekner A, Garami M, Hauser P, Hortob&#x000e1;gyi T, Bogn&#x000e1;r L, Wilson B, Hukin J, Carret AS, Van Meter TE, Nakamura H, Toledano H, Fried I, Fults D, Wataya T, Fryer C, Eisenstat DD, Scheineman K, Johnston D, Michaud J, Zelcer S, Hammond R, Ramsay DA, Fleming AJ, Lulla RR, Fangusaro JR, Sirachainan N, Larbcharoensub N, Hongeng S, Barakzai MA, Montpetit A, Stephens D, Grundy RG, Sch&#x000fc;ller U, Nicolaides T, Tihan T, Phillips J, Taylor MD, Rutka JT, Dirks P, Bader GD, Warmuth-Metz M, Rutkowski S, Pietsch T, Judkins AR, Jabado N, Bouffet E, Huang A. Molecular subgroups of atypical teratoid rhabdoid tumours in children: an integrated genomic and clinicopathological analysis. <span><span class="ref-journal">Lancet Oncol. </span>2015;<span class="ref-vol">16</span>:569–82.</span> [<a href="/pubmed/25882982" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25882982</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.van_den_munckhof.2012.1">van den Munckhof P, Christiaans I, Kenter SB, Baas F, Hulsebos TJ. Germline SMARCB1 mutation predisposes to multiple meningiomas and schwannomas with preferential location of cranial meningiomas at the falx cerebri. <span><span class="ref-journal">Neurogenetics. </span>2012;<span class="ref-vol">13</span>:1–7.</span> [<a href="/pubmed/22038540" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22038540</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.wieczorek.2013.5121">Wieczorek D, B&#x000f6;gershausen N, Beleggia F, Steiner-Haldenst&#x000e4;tt S, Pohl E, Li Y, Milz E, Martin M, Thiele H, Altm&#x000fc;ller J, Alanay Y, Kayserili H, Klein-Hitpass L, B&#x000f6;hringer S, Wollstein A, Albrecht B, Boduroglu K, Caliebe A, Chrzanowska K, Cogulu O, Cristofoli F, Czeschik JC, Devriendt K, Dotti MT, Elcioglu N, Gener B, Goecke TO, Krajewska-Walasek M, Guill&#x000e9;n-Navarro E, Hayek J, Houge G, Kilic E, Simsek-Kiper P&#x000d6;, L&#x000f3;pez-Gonz&#x000e1;lez V, Kuechler A, Lyonnet S, Mari F, Marozza A, Mathieu Dramard M, Mikat B, Morin G, Morice-Picard F, Ozkinay F, Rauch A, Renieri A, Tinschert S, Utine GE, Vilain C, Vivarelli R, Zweier C, N&#x000fc;rnberg P, Rahmann S, Vermeesch J, L&#x000fc;decke HJ, Zeschnigk M, Wollnik B. A comprehensive molecular study on Coffin-Siris and Nicolaides-Baraitser syndromes identifies a broad molecular and clinical spectrum converging on altered chromatin remodeling. <span><span class="ref-journal">Hum Mol Genet. </span>2013;<span class="ref-vol">22</span>:5121–35.</span> [<a href="/pubmed/23906836" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23906836</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.witkowski.2017.395">Witkowski L, Donini N, Byler-Dann R, Knost JA, Albrecht S, Berchuck A, McCluggage WG, Hasselblatt M, Foulkes WD. The hereditary nature of small cell carcinoma of the ovary, hypercalcemic type: two new familial cases. <span><span class="ref-journal">Fam Cancer. </span>2017;<span class="ref-vol">16</span>:395–9.</span> [<a href="/pmc/articles/PMC5487815/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5487815</span></a>] [<a href="/pubmed/27866340" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27866340</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="rtps.REF.zaky.2014.95">Zaky W, Dhall G, Ji L, Haley K, Allen J, Atlas M, Bertolone S, Cornelius A, Gardner S, Patel R, Pradhan K, Shen V, Thompson S, Torkildson J, Sposto R, Finlay JL. Intensive induction chemotherapy followed by myeloablative chemotherapy with autologous hematopoietic progenitor cell rescue for young children newly-diagnosed with central nervous system atypical teratoid/rhabdoid tumors: the Head Start III experience. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2014;<span class="ref-vol">61</span>:95–101.</span> [<a href="/pubmed/23934933" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23934933</span></a>]</div></li></ul></div></div><div id="rtps.Chapter_Notes"><h2 id="_rtps_Chapter_Notes_">Chapter Notes</h2><div id="rtps.Author_Notes"><h3>Author Notes</h3><p><b>Website:</b>
<a href="http://www.rhabdoid.de" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.rhabdoid.de</a></p><p>The European Rhabdoid Registry (EU-RHAB) was established in 2010 to define a standard of care for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> patients with malignant rhabdoid tumors, to further the understanding of basic molecular mechanisms by coordinating the collection and analysis of biologic materials in order to identify potential targets for pharmaceutical treatment, and eventually to shape the basis for Phase I/II trials.</p></div><div id="rtps.Acknowledgments"><h3>Acknowledgments</h3><p>We thank P Neumayer and I Lechner for expert assistance in data acquisition, management, and analysis.</p></div><div id="rtps.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>7 December 2017 (sw) Review posted live</div></li><li class="half_rhythm"><div>8 March 2017 (mcf) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK469816</span><span class="label">PMID: <a href="/pubmed/29215836" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">29215836</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/retinoblastoma/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/rcdp/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK469816&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK469816/?report=reader">PubReader</a></li><li><a href="/books/NBK469816/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK469816" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK469816" style="display:none" title="Cite this Page"><div class="bk_tt">Nemes K, Bens S, Bourdeaut F, et al. Rhabdoid Tumor Predisposition Syndrome. 2017 Dec 7. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK469816/pdf/Bookshelf_NBK469816.pdf">PDF version of this page</a> (496K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#rtps.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#rtps.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#rtps.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#rtps.Genetically_Related_Allelic_Disorde" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#rtps.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#rtps.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#rtps.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#rtps.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#rtps.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#rtps.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#rtps.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6597[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SMARCA4</a></li><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=6598[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SMARCB1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4474610" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4474610" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4474610" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4474610" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/27748099" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">BAP1</i> Tumor Predisposition Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">BAP1</i> Tumor Predisposition Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pilarski R, Rai K, Cebulla C, Abdel-Rahman M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25494491" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Rhabdoid tumor predisposition syndrome.</a><span class="source">[Pediatr Dev Pathol. 2015]</span><div class="brieflinkpop offscreen_noflow">Rhabdoid tumor predisposition syndrome.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sredni ST, Tomita T. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Pediatr Dev Pathol. 2015 Jan-Feb; 18(1):49-58. Epub 2014 Dec 10.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301488" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schneider K, Zelley K, Nichols KE, Garber J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301744" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">CDC73</i>-Related Disorders<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Hyde SM, Rich TA, Waguespack SG, Perrier ND, Hu MI. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29397238" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary SWI/SNF complex deficiency syndromes.</a><span class="source">[Semin Diagn Pathol. 2018]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hereditary SWI/SNF complex deficiency syndromes.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Agaimy A, Foulkes WD. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Semin Diagn Pathol. 2018 May; 35(3):193-198. Epub 2018 Feb 1.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=29215836" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=29215836" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e0410e8dd21425a259a09a7">Rhabdoid Tumor Predisposition Syndrome - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Rhabdoid Tumor Predisposition Syndrome - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:46:16-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8C0279E0406001000000000498017F&amp;ncbi_session=CE8C0279E0410E81_1176SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK469816%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK469816&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK469816/&amp;ncbi_pagename=Rhabdoid Tumor Predisposition Syndrome - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8C0279E0410E81_1176SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>